"We Are What We Are Supposed to Be": The Brothers Grimm as Fictional Representations

This article examines how the Brothers Grimm are fictionalized in German and Anglo-American media. While some representations revere and romanticize the iconic brothers for preserving the fairy-tale tradition, other depictions challenge the conventional understanding of their work and cultural contribution. In these demythologizing depictions, the Grimms appear ambiguous and even demonic. In recent representations, however, the Grimms—and their heirs—have been recast in positive roles that are both problematic and revealing. The persistent resurrection of the Grimms and the diverse roles they have been asked to play offer insight into the search for cultural myths, meaning, and identity

Children, War, and the Imaginative Space of Fairy Tales

Explores how children of war and adults reflecting on their violent wartime childhoods have had recourse to the space of fairy tales to interpret their traumatic physical environments and their emotional lives within them. To that end, the article (1) considers the nature of time and space in the classic fairy tale; (2) establishes how the ambiguity of fairy-tale spaces creates an imaginative geography that lends itself to the representation and mapping of wartime experience; and (3) uses examples from autobiographical accounts that show how fairy tales have been used to comprehend and to take emotional control over the war-torn landscape of childhood

Yours, Mine, or Ours? Perrault, the Brothers Grimm, and the Ownership of Fairy Tales

Fairy tales are often described in proprietary terms. Because the myth of their origin among the anonymous folk is so strong, the general tendency in both popular and scholarly discourse is to conceive of fairy tales as either the common property of all humanity or the treasures of specific cultures, nations, or ethnic groups. Since the publication of the Grimms' collection and the advent of copyrights laws, the idea of fairy tales as unique, protected individual possessions has emerged. This essays explores the implications these views have on the utilization of fairy tales and proposes a view of ownership that relies on the autonomy of individual reception

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe

Kiss and Tell: Orality, Narrative, and the Power of Words in "Sleeping Beauty"

Scholarship on the Sleeping Beauty tale has gone largely unappreciated. Underlying the story’s obvious themes and motifs—birth, death/sleep, rebirth—and complicating its gender dynamic is a preoccupation with orality and telling that gives the story a significant self-reflective dimension. This article examines how the tale reflects on storytelling and the medium of its telling, not only in the classical versions by Perrault and Grimm, but also in the Roman de Perceforest and Disney’s animated film

Is Seeing Believing? Proverbs and the Film Adaptation of a Fairy Tale

A study of the use of proverbs in the film The Company of Wolves (dir. Neil Jordan; screenplay by Jordan and Angela Carter), based on Angela Carter's adaptation of Little Red Riding Hood tales in her book The Bloody Chamber

Coleridge and Henry Boyd's Translation of Dante's "Inferno": Toward a Demonic Interpretation of "Kubla Khan"

Drawing on Henry Boyd's 1785 translation of the "Inferno," this note documents the nature and extent of Coleridge's knowledge of the "Inferno" and demonstrates that Dante's work probably did influence Coleridge during the composition of "Kubla Khan.

The Sleeping Script: Memory and Forgetting in Grimms' Romantic Fairy Tale (KHM 50)

The Grimms' tale of "Brier Rose" (KHM 50) has self-reflexive characteristics of the Romantic literary fairy tale. In thematizing memory and alluding to the imagery used in the preface to the Grimm brothers' collection of fairy tales, Wilhelm Grimm's version of the story self-consciously reflects on its own origins and exhibits a self-awareness more common to Romantic literature than to the natural and idealized folk tradition the collection purported to preserve